Petra Acquisition, Inc.
PAICU
NASDAQ Global Select10.75
USD
-0.41
- -
CIK
0001810560
ISIN
US7164212018
CUSIP
716421201
Return %
Stock
S&P500
1Y
- -
26.53
3Y
8.04
76.60
5Y
8.04
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Andreas A. Typaldos
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 5 West 21st Street New York City NY United States of America 10010
- IPO Date
- Oct 8, 2020
- CIK
- 0001810560
- Website
- petraacquisition.com
- Similar Companies
- Business
- Petra Acquisition, Inc. (PAICU) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant ongoing operations and focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. Incorporated in 2019 and headquartered at 5 West 21st Street in New York, New York, the company targets opportunities primarily in the United States without specified industry or sector restrictions. In January 2022, Petra Acquisition completed a reverse merger transaction whereby it was acquired by Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies such as REVTx-99 and REVDx-501, resulting in Petra being renamed Revelation Biosciences, Inc. and utilizing approximately $73 million in trust proceeds to fund clinical development.
Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut
Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.
PETRA ACQUISITION, INC. ANNOUNCES SECURITIES TO COMMENCE SEPARATE TRADING
U.S. IPO Week Ahead: Chinese EV's Billion-Dollar Deal Closes Out Summer In A 2-IPO Week